Safety of the blood supply in the united states: Opportunities and controversies

Annals of Internal Medicine

Volumn 127, Issue 10, 1997, Pages 904-909

  AuBuchon, James P ^a   Birkmeyer, John D ^a   Busch, Michael P ^b  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; BLOOD TRANSFUSION; COST EFFECTIVENESS ANALYSIS; HEALTH CARE QUALITY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; UNITED STATES; VIRUS INACTIVATION; VIRUS TRANSMISSION;

EID: 0030693384     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-127-10-199711150-00009     Document Type: Review

References (50)

1. Busch MP, Young MJ, Samson SM. Mosley JW, Ward JW, Perkins HA. Risk of human immunodeficiency virus (HIV) transmission by blood transfusions before the implementation of HIV-1 antibody screening. The Transfusion Safety Study Group. Transfusion. 1991;31:4-11.
2. Lackritz EM, Satten GA, Aberle-Grasse J, Dodd RY, Raimondi VP, Janssen RS. et al. Estimated risk of transmission of the human immunodeficiency virus by screened blood in the United States. N Engl J Med. 1995; 333:1721-5.
3. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ. The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study. N Engl J Med. 1996:334:1685-90.
4. Linden JV, Paul B, Dressler KP. A report of 104 transfusion errors in New York State. Transfusion. 1992:32:601-6.
5. Busch MP, Korelitz JJ. Kleinman SH, Lee SR, AuBuchon JP. Schreiber GB. Declining value of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion. 1995:35:903-10.
6. Nelson KE, Ahmed F, Stambolis V, Ness PM, Yawn D, McAlister H. Incident hepatitis C virus (HCV) and hepatitis virus (HBV) infections in transfused cardiac surgery patients: infection rates during different methods of donor screening. In: Glock M, McCurdy PR. Infectious Disease Testing for Blood Transfusions. Consensus Development Conference on Infectious Disease Testing for Blood Transfusions. Bethesda, MD: National Institutes of Health; 1995.
7. Kleinman S, Busch MP. General overview of transfusion-transmitted infections. In: Petz LD, Swisher SN, Kleinman S, Spense RK, Strauss RG, eds. Clinical Practice of Transfusion Medicine. 3d ed. New York: Churchill Livingstone; 1996.
8. Donahue JG, Munoz DV, Ness PM. Brown DE, Yawn DH, McAllister HA, et al. The declining risk of post-transfusion hepatitis C virus infection. N Engl J Med. 1992:327:369-73.
9. AuBuchon JP, Birkmeyer JD, Busch MP. Cost-effectiveness of expanded human immunodeficiency virus-testing protocols for donated blood. Transfusion. 1997;37:45-51.
10. Busch MP. Applications of molecular biology to infectious disease screening of blood donors. In: Allen RW, AuBuchon JP, eds. Molecular Genetics in Diagnosis and Research. Bethesda, MD: American Association of Blood Banks; 1995.
11. Ben-Hur E, Horowitz B. Virus inactivation in blood [Editorial]. AIDS. 1996; 10:1183-90.
12. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW. Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma. Blood. 1992;79:826-31.
13. Williamson LM, Allain JP. Wally inactivated fresh frozen plasma. Vox Sang. 1995;69:159-65.
14. Practice guidelines for blood component therapy. A report by the American Society of Anesthesiologists Task Force on blood component therapy. Anesthesiology. 1996:84:732-47.
15. Wallace EL, Churchill WH, Surgenor DM, An J, Cho G, McGurk S, et al. Collection and transfusion of blood and blood components in the United States, 1992. Transfusion. 1995:35:802-12.
16. Busch M, Glynn S. Schreiber G. Increased risk of viral transmission due to exclusion of older donors because of Creutzfeldt-Jakob disease (CJD). Retrovirus Epidemiology Donor Study [Abstract). Transfusion. 1996;36:59S.
17. Korelitz II, Busch MP, Williams AE. Antigen testing for human immunodeficiency virus (HIV) and the magnet effect: will the benefit of a new HIV test be offset by the numbers of higher risk, test-seeking donors attracted to blood centers? Retrovirus Epidemiology Donor Study. Transfusion. 1996;36: 203-8.
18. Lefrere 11, Loiseau P, Martinot-Peignoux M, Mariotti M, Ravera N, Thauvin M, et al. Infection by hepatitis C virus through contaminated intravenous immune globulin: results of a prospective national inquiry in France. Transfusion. 1996:36:394-7.
19. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ, et al. Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA. 1996:276:1563-7.
20. Normann A, Graff A, Gerritzen A, Brackmann HH, Flehmig B. Detection of hepatitis A virus RNA in a commercially available factor VIII preparation [Letter]. Lancet. 1992;340:1232-3.
21. Cohen BJ, Field AM, Gudnadottir S, Beard S, Barbara JA. Blood donor screening for parvovirus B19. J Virol Methods. 1990;30:233-8.
22. AuBuchon JP, Birkmeyer JD. Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA. 1994;272: 1210-4.
23. Lynch TJ, Weinstein MJ, Tankersley DL, Fratantoni JC, Finlayson JS. Considerations of pool size in the manufacture of plasma derivatives. Transfusion. 1996:36:770-5.
24. Birkmeyer JD, AuBuchon JP, Littenberg B, O'Connor GT, Nease RF Jr, Nugent WC, et al. Cost-effectiveness of preoperative autologous donation in coronary bypass grafting. Ann Thoracic Surg. 1994;57:161-9.
25. Popovsky MA, Whitaker B. Arnold NL Severe outcomes of allogeneic and autologous blood donation: frequency and characterization. Transfusion. 1995:35:734-7.
26. Mintz PD. Undertransfusion [Editorial]. Am J Clin Pathol. 1992:98:150-1.
27. Evans RW. Cost-effectiveness analysis of transplantation. Surg Clin North Am. 1986:66:603-16.
28. Weinstein MC, Stason WB. Cost-effectiveness of coronary artery bypass surgery. Circulation. 1982:66(5 Pt 2):IIIS6-66.
29. Elixhauser A. Costs of breast cancer and the cost-effectiveness of breast cancer screening. Int J Technol Assess Health Care. 1991;7;604-15.
30. Edelson JT, Weinstein MC, Tosteson AN, Williams L, Lee TH, Goldman L Long-term cost-effectiveness of various initial monotherapies for mild to moderate hypertension. JAMA. 1990:263:407-13.
31. Baske TF, Parsons ML Prevention of Rh(D) alloimmunization: a costbenefit analysis. Can Med Assoc J. 1990:142:337-9.
32. Birkmeyer JD, Goodnough LT, AuBuchon JP, Noordsij PG, Littenberg B. The cost-effectiveness of preoperative autologous blood donation for total hip and knee replacement. Transfusion. 1993;33:544-51.
33. Etchason J, Petz L Keeler E, Calhoun L, Kleinman S, Snider C, et al. The cost effectiveness of preoperative autologous blood donations. N Engl J Med. 1995:332:719-24.
34. Vamvakas EC Taswell HF. Long-term survival after blood transfusion. Transfusion. 1994:34:471-7.
35. Evans RW. A critical perspective on the tools to support clinical decision making [Editorial]. Transfusion. 1996:36:671-3.
36. Russell LB, Gold MR, Siegel JE, Daniels N, Weinstein MC. The role of cost-effectiveness analysis in health and medicine. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996:276:1172-7.
37. Weinstein MC, Siegel JE. Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996:276:1253-8.
38. Siegel JE, Weinstein MC, Russell LB, Gold MR. Recommendations for reporting cost-effectiveness analyses. Panel on Cost-Effectiveness in Health and Medicine. JAMA. 1996:276:1339-41.
39. Schneiderman U, Kaplan RM. Fear of dying and HIV infection vs hepatitis B infection. Am J Public Health. 1992:82:584-6.
40. Fowler FJ Jr, Cleary PO, Massagli MP, Weissman J, Epstein A. The role of reluctance to give up life in the measurement of the values of health states. Med Decis Making. 1995:15:195-200.
41. Morgan MG. Risk analysis and management. Sei Am. 1993:269: 38-41.
42. Hadorn DC. Setting health care priorities in Oregon. Cost-effectiveness meets the rule of rescue. JAMA. 1991:265:2218-25.
43. Hux JE, Leviton CM, Naylor CD. Prescribing propensity: influence of lifeexpectancy gains and drug costs. J Gen Intern Med. 1994:9:195-201.
44. Rose G. Sick individuals and sick populations. Int J Epidemiol. 1985:14:32-8.
45. Korelitz JJ, Busch MP, Kleinman SH, Williams AE, Zuck TF, Gilcher RO, et al. Relationship between antibody to hepatitis B core antigen and retroviral infections in blood from volunteer donors. Transfusion. 1996:36:232-7.
46. Leveton L, Sox HC, Stoto M, eds. HIV and the Blood Supply: An Analysis of Crisis Decision Making. Washington, DC: National Academy Pr: 1995.
47. Shuts R. And the Band Played On: Politics, People, and the AIDS Epidemic. New York: St. Martin's Pr; 1987.
48. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, AuBuchon JP, Schreiber GB. Declining yield of alanine aminotransferase in screening of blood donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. Transfusion. 1995:35:903-10.
49. Infectious disease testing for blood transfusions. NIH Consensus Development Panel on Infectious Disease Testing for Blood Transfusions. JAMA. 1995;274: 1374-9.
50. AuBuchon JP, Birkmeyer JD, Busch MP, Dodd RY, Lackritz EM, Petersen LR. Cost-effectiveness of anti-HBc testing to reduce HIV transmission risk [Abstract]. Transfusion. 1996;36:43S.